Tag: Non hodgkin s lymphoma

The biologic drug Rituxan® was first approved by the FDA in 1997, and its generic name is rituximab. This monoclonal antibody has become a cornerstone therapy for various cancers and autoimmune conditions, with several biosimilar versions now available to offer patients more affordable options.

The U.S. Food and Drug Administration (FDA) first approved Truxima (rituximab-abbs) in 2018 as a biosimilar to Rituxan [1.3.1]. This raises a critical question for patients and providers: Is Truxima as good as Rituxan? This article examines the evidence.

The first Rituxan infusion typically takes 4 to 6 hours or even longer, primarily due to the slow infusion rate to monitor for potential reactions. Understanding **how long do Rituxan infusions last?** is crucial for proper treatment planning, as subsequent sessions are often significantly shorter.

Ibritumomab, sold under the brand name Zevalin, is a specialized radioimmunotherapy drug that was FDA-approved in 2002 for treating certain types of B-cell non-Hodgkin's lymphoma (NHL). The treatment delivers targeted radiation directly to cancerous cells via a monoclonal antibody, making it a powerful tool in cancer therapy.

According to studies on patients with rheumatoid arthritis, ineffectiveness accounts for a significant portion of rituximab discontinuations, sometimes as high as 46%. However, pinpointing the single most common reason for discontinuing rituximab is more complex, as the primary drivers vary considerably depending on the specific disease being treated and individual patient factors.